To the Editor:

Sarcoidosis is characterised by an accumulation of CD4^+^ T-cells in the lungs and an increased bronchoalveolar lavage fluid (BALF) CD4/CD8 ratio (\>3.5) \[[@C1]\]. In sarcoidosis, an expansion of BALF CD4^+^ T-cells expressing the T-cell receptor Vα2.3 has been associated with good prognosis and with specific HLA-alleles, *i.e.* HLA-DRB1\*0301 and HLA-DRB3\*0101 (which is often carried together with HLA-DRB1\*13). HLA-DRB1\*03 and HLA-DRB3\*0101 molecules show similarities in the region important for antigen presentation and both may therefore be capable of presenting identical antigens to the lung T-cells \[[@C2]\]. Furthermore, an expansion defined as \>10.5% CD4^+^ Vα2.3^+^ BALF T-cells is commonly seen in patients with Löfgren\'s syndrome \[[@C3]\], which is characterised by an acute onset with bilateral ankle arthritis and/or erythema nodosum, bilateral hilar lymphadenopathy and, in some cases, with parenchymal infiltrates and usually fever \[[@C4]\]. We have previously shown that very high expansions of CD4^+^ Vα2.3^+^ T-cells are associated with Löfgren\'s syndrome and a disease duration \<2 years \[[@C3]\]. However, not all patients with an expansion of CD4^+^ Vα2.3^+^ T-cells have Löfgren\'s syndrome and resolving disease. In this much enlarged study on a HLA-typed sarcoidosis cohort, we aimed at investigating the clinical characteristics of patients with an expansion of CD4^+^ Vα2.3^+^ T-cells in BALF and to analyse if the degree of expansion may predict the prognosis of sarcoidosis.

In a registry of sarcoidosis patients (n=661, including 252 with Löfgren\'s syndrome), all investigated with bronchoscopy and BAL for diagnostic purposes and HLA-typed and followed for at least 2 years, 248 subjects were identified with BALF CD4^+^ Vα2.3^+^ T-cells expansions. An expansion was defined as three times the median percentage of Vα2.3^+^ CD4^+^ T cells in peripheral blood of healthy subjects, as previously described (3×3.5%) \[[@C3]\]. Disease activity was evaluated 2 years after disease onset, considering presence of symptoms (*e.g.* cough, fatigue, dyspnoea, fever), serum-ACE activity, spirometry values and chest radiographic findings. Patients without any pathological findings were regarded to have a resolving disease.

We focused on patients with Vα2.3^+^ CD4^+^ T-cell expansions, out of which 73% had classical Löfgren\'s syndrome ([table 1](#TB1){ref-type="table"}). They were all judged to have active disease at the time for bronchoscopy. The percentage of Vα2.3^+^ CD4^+^ T-cells in BALF is known to be normalised when the patients recover \[[@C5]\]. All patients were without immunosuppressive treatment at the time for bronchoscopy. After 2 years follow-up very few patients with Löfgren\'s syndrome, but some more with non-Löfgren\'s syndrome, had been treated with immunosuppressants. The sarcoidosis diagnosis was made through typical clinical and radiographic manifestations, findings at bronchoscopy with BAL including an elevated CD4/CD8-ratio (\>3.5) and/or positive biopsies, in accordance with the criteria of the World Association of Sarcoidosis and other Granulomatous Disorders \[[@C6]\]. Chest radiographs were evaluated as previously described \[[@C7]\]. Written informed consent was obtained from all subjects, and approval was granted from the regional ethical review board.

###### 

Clinical characteristics of patients with Vα2.3^+^ T-cells \>10.5% in bronchoalveolar lavage fluid (BALF)

                                                   **LS**            **Non-LS**
  ------------------------------------------ ------------------- -------------------
  **Subjects**                                       180                 68
  **Male/female**                                  111/69               41/27
  **Age years**^\#^                              37 (21--62)         45 (26--72)
  **Radiographic stage 0/I/II/III/IV**^\#^      0/123/57/0/0         4/16/36/8/4
  **Resolving/non-resolving**^\#^                  166/14               25/43
  **CD4/CD8 ratio**\*                          9.8 (0.9--56.8)     7.1 (1.2--24.0)
  **% Vα2.3 BALF cells**^\#^                  28.4 (11.0--50.0)   17.8 (11.4--44.3)
  **HLA-DRB1\*03^+^/^−^**                          155/25               36/32
  **Vα2.3 BALF cells %**                                         
   HLA-DRB1\*03^+\#^                                29.9                20.5
   HLA-DRB1\*03^−^\*\*                              19.8                14.8
  **Patients recovered %**                                       
   HLA-DRB1\*03^+\#^                                 94                  39
   HLA-DRB1\*03^−^\*\*                               80                  34

Data are presented as n or mean (range), unless otherwise stated. LS: Löfgreńs syndrome. \*: p\<0.05, \*\*: p\<0.001 and ^\#^: p\<0.0001, comparing differences between patients with LS and non-LS and for radiological stage differences between stage I and II.

Bronchoscopy with BAL was carried out as described before \[[@C8]\]. Surface markers expressed on T-cells were analysed using flow cytometry and all patients were HLA-typed as previously described \[[@C9], [@C10]\].

Statistical analyses were performed with Graph Pad Prism 6 (GraphPad Software Inc., San Diego, CA, USA). When comparing several groups such as differences between HLA-DRB1\* alleles, p\<0.003 (p\<0.05 divided by 13) was regarded as significant after Bonferroni correction for the number of alleles (n=13), and otherwise p\<0.05 was regarded as significant.

High percentages of CD4^+^ Vα2.3^+^ T-cells (*i.e.* Vα2.3^+^ CD4^+^ T-cells \>10.5% in BALF) associated with a resolving disease, as 77% (191 out of 248) of these patients resolved within 2 years compared with 28% (114 out of 413) of patients with normal levels (p\<0.0001). The proportion of patients who recovered increased gradually with the increasing proportion of CD4^+^ Vα2.3^+^ T-cells in BALF, for example in patients with 0--5% of CD4^+^ Vα2.3^+^ T-cells 25% had resolving disease; in the range 11--15%, 44% resolved and when there were 21--25% Vα2.3^+^ T-cells, 82% resolved. If \>30%, 95% resolved.

Patients with Löfgren\'s syndrome had higher proportion of CD4^+^ Vα2.3^+^ T-cells in BALF compared to non-Löfgren\'s syndrome patients and were also younger at disease onset ([table 1](#TB1){ref-type="table"}). Furthermore, patients with Löfgren\'s syndrome who carried the HLA-DRB1\*03 allele had a higher median CD4^+^ Vα2.3^+^ T-cell proportion in BALF compared to HLA-DRB1\*03^−^ with Löfgren\'s syndrome (p\<0.0001). Among the HLA-DRB1\*03^−^ patients, HLA-DRB1\*13 was carried by 88% of the patients with Löfgren\'s syndrome and by 63% with non-Löfgren\'s syndrome.

In this study, we chose to focus on patients with an expansion of CD4^+^ Vα2.3^+^ T-cells in BALF. The highest proportion of CD4^+^ Vα2.3^+^ T-cells in the present study was seen in Löfgren\'s syndrome patients who were HLA-DRB1\*03^+^. The non-LS group was characterised by a less pronounced expansion of Vα2.3^+^ T-cells and disease onset at a higher age. That older patients have less favourable outcome has been shown in another cohort \[[@C11]\].

Our hypothesis is that patients with expansion of CD4^+^ Vα2.3^+^ T-cells (*i.e.* Vα2.3^+^ CD4^+^ T-cells \>10.5% in BALF) may have a more effective eradication of a presumed disease-promoting antigen. An influx of CD4^+^ Vα2.3^+^ T-cells to the lungs may then explain the concomitant pronounced CD4/CD8 ratio. We have in a previously study showed that the BALF CD4^+^ Vα2.3^+^ T-cells express significantly reduced levels of FOXP3 *versus* CD4^+^ Vα2.3^−^ T-cells \[[@C12]\], suggesting the CD4^+^ Vα2.3^+^ T-cells function as effector cells rather than regulatory cells, in line with a hypothetically more efficient elimination of a hypothetical sarcoidosis-antigen by such T-cells.

The clinical presentation, *i.e.* Löfgren\'s syndrome or non-Löfgren\'s syndrome, may reflect an altered immune and inflammatory reaction influenced by different exposures or genetic differences, which also include other inflammatory genes (*e.g.* tumour necrosis factor gene variants linked to HLA-DRB1\*03 variants). A hypothetical antigen might itself also have properties that may influence the inflammatory reaction, *e.g.* by inducing auto-immune reactions due to similarities of the inciting antigen and some self-structures or by preferentially stimulating a T helper (Th) 1-, Th 2- or a Th 17-dominant response.

In conclusion, the findings in this study indicate that the more pronounced the expansion of CD4^+^ Vα2.3^+^ T-cells in the BAL fluid is, the better the prognosis. The usefulness of Va2.3^+^ T-cells as a prognostic marker is described here for a Scandinavian cohort. Whether they may be of clinical interest in other populations needs to be analysed in future studies.
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